GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Infinity Pharmaceuticals INFIQ · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Infinity Pharmaceuticals — daily INFIQ Delayed
Market value
$91
Last close × shares
Volume
29k
Shares, 9 Nov 2026

About Infinity Pharmaceuticals

Its shares trade under the ticker INFIQ. It has been listed since 27 July 2000. In the fiscal year to 31 December 2022, it reported revenue of $2.6m and a net loss of $44.4m. At that date it held total assets of $42.2m and shareholders' equity of −$19.1m.

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2000-07-27. The firm is engaged in the discovery, development and delivery of medicines to treat diseases. The firm develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The firm is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The firm also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Figures and description from our data supplier, not checked against the company's own report.

More about Infinity Pharmaceuticals →

Latest on Infinity Pharmaceuticals

Our reporting

We have not reported on Infinity Pharmaceuticals yet.

Next results

16 Nov 2026

Due on 16 Nov 2026. Analysts expect earnings of -0.13 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Infinity Pharmaceuticals's ticker?

Infinity Pharmaceuticals trades as INFIQ on its US listing, under ISIN US45665G3039.

What was Infinity Pharmaceuticals's last closing price?

0.00 on 9 Nov 2026. The figure is in USD and is never converted.

When does Infinity Pharmaceuticals next report results?

Results are expected on 16 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.